Nursing Elites

1. A client with a new prescription for Escitalopram for the treatment of generalized anxiety disorder is being taught by a healthcare provider. Which statement by the client indicates understanding of the teaching?

• A. I should take the medication on an empty stomach.
• B. I will follow a low-sodium diet while taking this medication.
• C. I need to discontinue this medication slowly.
• D. I should not crush this medication before swallowing.

Correct answer: C

Rationale: The correct answer is C. When discontinuing escitalopram, the client should taper the medication slowly according to a prescribed tapered dosing schedule to reduce the risk of withdrawal syndrome. This gradual reduction helps minimize potential withdrawal symptoms and ensures a safer discontinuation process. Choices A, B, and D are incorrect because taking escitalopram on an empty stomach, following a low-sodium diet, and not crushing the medication are not directly related to the safe and effective use of the medication or its discontinuation process.

2. In which patient could the drug Senna potentially be indicated?

• A. A patient with an eating disorder
• B. A patient who has not passed stool in 5 days
• C. A patient with anal fissures
• D. A patient with a history of hemorrhoids

Correct answer: B

Rationale: Senna is a stimulant laxative commonly used to treat constipation by stimulating bowel movements. It is typically indicated for patients who have not passed stool in several days, thereby helping to relieve constipation. Patients with eating disorders may require different treatments related to their condition. Patients with anal fissures or a history of hemorrhoids may need treatments targeted at those specific issues, which may not involve Senna.

3. A client is taking lisinopril. Which of the following outcomes indicates a therapeutic effect of the medication?

• A. Decreased blood pressure
• B. Increase in HDL cholesterol
• C. Prevention of bipolar manic episodes
• D. Improved sexual function

Correct answer: A

Rationale: The therapeutic effect of lisinopril, an ACE inhibitor, is indicated by a decrease in blood pressure. Lisinopril works by relaxing blood vessels, leading to a reduction in blood pressure. Monitoring and achieving a decrease in blood pressure is a key outcome when managing hypertension with lisinopril. Choices B, C, and D are incorrect because lisinopril is not intended to increase HDL cholesterol, prevent bipolar manic episodes, or improve sexual function. Therefore, the correct outcome indicating the therapeutic effect of lisinopril is a decrease in blood pressure.

4. A client has a new prescription for Docusate Sodium. Which of the following instructions should the nurse include?

• A. Take the medication with a full glass of water.
• B. Expect results within 30 minutes.
• C. Take this medication at bedtime.
• D. Avoid taking this medication with food.

Correct answer: A

Rationale: The correct instruction for a client prescribed Docusate Sodium is to take the medication with a full glass of water. Docusate sodium is a stool softener, and taking it with water helps to soften the stool and make bowel movements easier. Adequate fluid intake is crucial when taking stool softeners to prevent constipation. Choices B, C, and D are incorrect. B is incorrect because the effects of Docusate Sodium may not be immediate, and it may take a couple of days for the stool softener to work. Choice C is incorrect as there is no specific requirement to take this medication at bedtime. Choice D is incorrect because there is no instruction to avoid taking Docusate Sodium with food.

5. What should you monitor when administering Clopidogrel to a patient?

• A. Signs of thrombotic thrombocytopenic purpura
• B. Bleeding during therapy
• C. CBC with differential and platelet count
• D. All of the above

Correct answer: D

Rationale: When administering Clopidogrel, it is crucial to monitor for signs of thrombotic thrombocytopenic purpura, bleeding during therapy, and changes in CBC with differential and platelet count. Thrombotic thrombocytopenic purpura is a rare but serious condition associated with Clopidogrel use, characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, fever, and renal dysfunction. Monitoring for signs of thrombotic thrombocytopenic purpura is essential to detect this potentially life-threatening condition early. Monitoring for bleeding helps to assess the risk of hemorrhagic events, a known side effect of Clopidogrel. Additionally, regular monitoring of CBC with differential and platelet count is necessary to evaluate the drug's impact on blood cell counts and detect any abnormalities that may require intervention. Therefore, monitoring all these parameters is vital to ensure patient safety and appropriate management during Clopidogrel therapy.

Similar Questions